focused on the late-stage development and commercialization of easy-to-use, blood-based tests to address unmet clinical needs in cancer surveillance and eventually early-detection. We have discovered, validated and developed new easy-to-use tests to detect novel tumor protein biomarkers with real-world clinical utility.